US Pharma MarketingExclusive: Typewriter raises $56M for jumping-gene tech, in vivo CAR-T
Typewriter Therapeutics raises $56M Series A to build RNA-based jumping-gene therapies for in vivo CAR-T and genetic liver disease. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo…
Moving pieces of genetic code commonly called “jumping genes” could give scientists a long-sought way to transplant full genes into the human body without viral delivery vehicles or bacterial-derived enzymes like CRISPR.
...
Source: Endpoints News